No Data
No Data
No Data
No Data
No Data
TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting
WALTHAM, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies
GlobeNewswireApr 25 04:05
TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares
WALTHAM, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies
GlobeNewswireApr 24 23:03
Unveiling 4 Analyst Insights On TScan Therapeutics
TScan Therapeutics (NASDAQ:TCRX) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.The table below provides a concise overview of recent
BenzingaApr 24 02:01
Wedbush: Reiterates the TSCAN Therapeutics (TCRX.US) rating and adjusted from better than market to better than market rating, with a target price of $10.00.
Wedbush: Reiterates the TSCAN Therapeutics (TCRX.US) rating and adjusted from better than market to better than market rating, with a target price of $10.00.
Zhitong FinanceApr 24 01:20
Wedbush Reiterates Outperform on TScan Therapeutics, Maintains $10 Price Target
Wedbush analyst David Nierengarten reiterates TScan Therapeutics with a Outperform and maintains $10 price target.
Analyst UpgradesApr 24 01:17
TScan Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/23/2024 38.31% Wedbush → $10 Reiterates Outperform → Outperform 03/07/2024 24.48% Barclays $7 → $9 Main
BenzingaApr 24 01:15
No Data
No Data